000898868 000__ 04636cam\a2200517Ii\4500
000898868 001__ 898868
000898868 005__ 20230306150247.0
000898868 006__ m\\\\\o\\d\\\\\\\\
000898868 007__ cr\cn\nnnunnun
000898868 008__ 190717t20192019sz\\\\\\ob\\\\001\0\eng\d
000898868 020__ $$a9783030214777$$q(electronic book)
000898868 020__ $$a303021477X$$q(electronic book)
000898868 020__ $$z9783030214760
000898868 035__ $$aSP(OCoLC)on1108871756
000898868 035__ $$aSP(OCoLC)1108871756
000898868 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dEBLCP$$dOCLCF$$dUKMGB$$dGW5XE
000898868 049__ $$aISEA
000898868 050_4 $$aRM301.63
000898868 08204 $$a615.7$$223
000898868 24500 $$aCurrent applications for overcoming resistance to targeted therapies /$$ceditors, Myron R. Szewczuk, Bessi Qorri and Manpreet Sambi.
000898868 264_1 $$aCham, Switzerland :$$bSpringer Nature,$$c[2019]
000898868 264_4 $$c©2019
000898868 300__ $$a1 online resource.
000898868 336__ $$atext$$btxt$$2rdacontent
000898868 337__ $$acomputer$$bc$$2rdamedia
000898868 338__ $$aonline resource$$bcr$$2rdacarrier
000898868 4901_ $$aResistance to targeted anti-cancer therapeutics ;$$vv. 20
000898868 504__ $$aIncludes bibliographical references and index.
000898868 5050_ $$aIntro; Aims and Scope; Series Editor Biography; Acknowledgment; Preface; Contents; Contributors; About the Editors; Chapter 1: Introduction to the Acquisition of Resistance to Targeted Therapy; 1.1 Introduction; 1.2 Molecular Events Leading to the Acquisition of Resistance to Targeted Therapy; 1.2.1 Alterations in Drug Target Expression to Prevent Therapeutic Action; 1.2.2 Activation of Compensatory Pathways; 1.2.3 Activation of Alternative Pathways to Ensure Survival; 1.2.4 Epigenome: Regulating Acquired Resistance and Modifying Drug Activity
000898868 5058_ $$a1.3 Cellular Events Contributing to the Development of Resistance1.3.1 Transformation/Dedifferentiation Mechanisms and Indirect Resistance to Therapeutic Action; 1.3.2 The Tumor Microenvironment and the Development of Resistance to Targeted Therapies; 1.3.3 The Activity of Drug Efflux Transporters; 1.3.4 Other Considerations of Mechanisms Potentially Contributing to the Acquisition of Resistance; 1.4 Specific Mechanisms of Acquired Resistance to Select Targeted Therapies; 1.4.1 Mechanisms of Resistance to Anti-Angiogenic Therapy; 1.4.2 Resistance to Tyrosine Kinase Inhibitors
000898868 5058_ $$a1.4.3 Resistance to Anti-Apoptosis Inhibitors1.5 Future Directions of Targeted Therapy; References; Chapter 2: Targeting the Tumor Microenvironment to Overcome Resistance to Therapy; 2.1 Introduction; 2.2 Key Components of the Tumor Microenvironment That Contribute to the Acquisition of Resistance; 2.2.1 Extracellular Matrix Regulation of Invasion and Metastasis; 2.2.2 Soluble Factors in the Tumor Microenvironment Modulate Tumor-Stromal Crosstalk; 2.2.3 Inflammation and Immunity Modulate the Tumorigenic Niche; 2.2.4 The Angiogenic Switch in Tumorigenesis
000898868 5058_ $$a2.2.5 Exosomes Are the Transporters of the Tumor Microenvironment2.3 Targeting the Tumor Microenvironment to Overcome Resistance to Therapy; 2.3.1 Discovering a Novel Role of Neuraminidase-1 Activity in Multistage Tumorigenesis; 2.3.2 Role of GPCR Transactivation in Neuraminidase-1 Activity; 2.3.3 Targeting Neuraminidase-1 Activity as the Achilles Heel of the Tumor Microenvironment; 2.4 Conclusions; References; Chapter 3: Current Challenges and Applications of Oncolytic Viruses in Overcoming the Development of Resistance to Therapies in Cancer; 3.1 Introduction; 3.2 Types of Oncolytic Viruses
000898868 5058_ $$a3.2.1 Adenovirus3.2.2 Herpes Simplex Virus 1 (HSV-1); 3.2.3 Vaccinia Virus (VV); 3.2.4 Reovirus Type 3 Dearing; 3.2.5 Measles Virus (MV); 3.2.6 Poliovirus (PV); 3.2.7 Coxsackievirus (CV); 3.2.8 Vesicular Stomatitis Virus (VSV); 3.2.9 Maraba Virus (MRB); 3.3 Oncolytic Viral Targeting of the Tumor Vasculature; 3.4 Targeting Components of the Tumor Extracellular Matrix with Virotherapy to Overcome Therapy Resistance; 3.4.1 Tumor Extracellular Matrix Limits Oncolytic Virus Efficacy; 3.4.2 ECM-Modifying OVs Can Overcome ECM-Mediated Resistance
000898868 506__ $$aAccess limited to authorized users.
000898868 588__ $$aOnline resource; title from PDF title page (viewed July 18, 2019).
000898868 650_0 $$aDrug targeting.
000898868 650_0 $$aDrug resistance in cancer cells.
000898868 650_0 $$aLungs$$xCancer$$xTreatment.
000898868 7001_ $$aSzewczuk, Myron R.,$$eeditor.
000898868 7001_ $$aQorri, Bessi,$$eeditor.
000898868 7001_ $$aSambi, Manpreet,$$eeditor.
000898868 830_0 $$aResistance to targeted anti-cancer therapeutics ;$$vv. 20.
000898868 852__ $$bebk
000898868 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-030-21477-7$$zOnline Access$$91397441.1
000898868 909CO $$ooai:library.usi.edu:898868$$pGLOBAL_SET
000898868 980__ $$aEBOOK
000898868 980__ $$aBIB
000898868 982__ $$aEbook
000898868 983__ $$aOnline
000898868 994__ $$a92$$bISE